← Back to Clinical Trials
Recruiting NCT07147660

NCT07147660 Vision on the Road: Vision Rehabilitation for Driving After Stroke

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07147660
Status Recruiting
Phase
Sponsor University of South-Eastern Norway
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 52 participants
Start Date 2025-03-28
Primary Completion 2027-12

Eligibility & Interventions

Sex All sexes
Min Age 20 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
Compensatory scanning trainingDelayed Compensatory scanning training

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 52 participants in total. It began in 2025-03-28 with a primary completion date of 2027-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to learn if vision training works to improve functional vision in people with visual field loss after stroke. The investigators want to know more about how people perceive their own functional vision and ability to compensate for visual field loss in daily activities. The main questions the study aims to answer are: * Does vision training improve dimensions of functional vision? * How does vision training affect the participants's perception of functional vision and the ability to compensate for visual field loss? Researchers will compare the effect of home-based vision training to standard care (no vision training) on functional vision. Participants will: * Participate in home-based vision training or standard care for 8 weeks * Be contacted once a week by phone * Keep a training diary

Eligibility Criteria

Inclusion criteria: * Adults aged 20-85 years with a visual field defect following stroke * Norwegian Class 1 driving licence revoked no more than five years ago * Speak a Scandinavian language * Able to provide written informed consent * Motivated and willing to participate in study activities for a total of 20 to 28 weeks * Own a personal computer (for digital follow-up and online vision training) * Able to travel to Oslo for data collection Exclusion criteria: * Presence of strabismus and/or visual neglect * Eye disease or other health conditions that do not meet the health requirements for a Norwegian Class 1 driver's license * Cognitive impairment, dementia, severe psychiatric diagnosis, or inability to provide written informed consent

Contact & Investigator

Central Contact

Marte Rosenvinge, phd-student

✉ marte.rosenvinge@usn.no

📞 +47 31 00 92 05

Principal Investigator

Helle Falkenberg, Professor

PRINCIPAL INVESTIGATOR

University of South-Eastern Norway

Frequently Asked Questions

Who can join the NCT07147660 clinical trial?

This trial is open to participants of all sexes, aged 20 Years or older, up to 85 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07147660 currently recruiting?

Yes, NCT07147660 is actively recruiting participants. Contact the research team at marte.rosenvinge@usn.no for enrollment information.

Where is the NCT07147660 trial being conducted?

This trial is being conducted at Kongsberg, Norway, Oslo, Norway.

Who is sponsoring the NCT07147660 clinical trial?

NCT07147660 is sponsored by University of South-Eastern Norway. The principal investigator is Helle Falkenberg, Professor at University of South-Eastern Norway. The trial plans to enroll 52 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology